 Connection
Ashley Frazer-Abel to Male
This is a "connection" page, showing publications Ashley Frazer-Abel has written about Male.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.147 |
|
|
|
-
Bettcher BM, Ren S, Wang Y, Carlson NE, Lippitt WL, McConnell BV, Wilson EN, Shapiro ALB, Coughlan C, Carlisle TC, Unger JR, Cook GG, Bengtson K, Gorla L, Ueberheide BM, Kanshin E, Potter H, Schulz L, Frazer-Abel A, Pelak VS. Relation of blood-based inflammation conditional networks to key immune health status and Alzheimer's biomarkers in aging adults. Neurobiol Aging. 2026 Oct; 166:14-28.
Score: 0.009
-
Deane KD, Striebich CC, Feser ML, O'Dell JR, James JA, Sparks JA, Davis JM, Graf J, McMahon MA, Solow EB, Forbess LJ, Tiliakos A, Schiopu E, Danila MI, Horowitz DL, Kay J, Strickland CD, Guthridge JM, Arriens C, Grossman JM, Kristen Demoruelle M, Bemis EA, Frazer-Abel A, Fleischer CL, Fox DA, Mikuls TR, Greenleaf M, York K, Walker S, Keyes-Elstein L, Byron M, Fedler J, Goldmuntz EA, Holers VM. A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis. Arthritis Rheumatol. 2026 Apr; 78(4):809-820.
Score: 0.009
-
Barbour SJ, Hladunewich MA, McCaleb ML, Robson R, Barrett TD, Yin L, Frazer-Abel A, Garg JP, Geary R, Schneider E, Brice GT. A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathy. Kidney Int. 2026 Mar; 109(3):592-601.
Score: 0.009
-
E de Carlo Forest T, Marin AI, Gill Z, Gnanaraj R, Patnaik JL, Poppelaars F, Lynch AM, Palestine AG, Mathias MT, Manoharan N, Frazer-Abel AA, Holers VM, Mandava N. Association between systemic complement levels and choroidal thickness in advanced non-neovascular age-related macular degeneration. Sci Rep. 2025 Dec 06; 16(1):1442.
Score: 0.009
-
Hu X, Webb-Robertson BM, Parikh HM, Nakayasu ES, Onengut-Gumuscu S, Chen WM, Frazer-Abel A, Metz TO, Rich SS, Rewers MJ, Manichaikul A. Genetic mapping of complement system proteins for islet autoimmunity in children with high risk of T1D. Commun Biol. 2025 Sep 26; 8(1):1366.
Score: 0.008
-
Lynch AM, Grove NC, Wagner BD, Palestine AG, Holers VM, Frazer-Abel AA, Gnanaraj R, Lisker-Cervantes A, Patnaik JL, de Carlo Forest TE, Auer EA, McReynolds AJ, Mathias MT, Manoharan N, Rodriquez De Cordoba S, Mandava N. Dynamic Risk of Systemic Complement Activation With Time to Progression to Advanced Age-Related Macular Degeneration. JAMA Ophthalmol. 2025 Aug 01; 143(8):634-642.
Score: 0.008
-
McCaleb ML, Hughes SG, Grossman TR, Frazer-Abel A, Jung B, Yin L, Henry SP, Monia BP, Schneider E, Geary R, Brice GT. Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen. Immunobiology. 2025 03; 230(2):152876.
Score: 0.008
-
Petrow E, Feng C, Frazer-Abel A, Marangoni RG, Lutz K, Nichols WC, Holers VM, Ritchlin C, White RJ, Korman BD. Utility of factor D and other alternative complement factors as biomarkers in systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH). Semin Arthritis Rheum. 2024 12; 69:152554.
Score: 0.008
-
Frost E, Hofmann JN, Huang WY, Frazer-Abel AA, Deane KD, Berndt SI. Serum levels of B-cell activating factor are associated with a reduced risk of chronic lymphocytic leukemia. Blood Cancer J. 2024 08 07; 14(1):132.
Score: 0.008
-
Marin AI, Poppelaars F, Wagner BD, Palestine AG, Patnaik JL, Holers VM, Frazer-Abel AA, Mathias MT, Manoharan N, Fonteh CN, Mandava N, Lynch AM. Sex and Age-Related Differences in Complement Factors Among Patients With Intermediate Age-Related Macular Degeneration. Transl Vis Sci Technol. 2022 05 02; 11(5):22.
Score: 0.007
-
Okamoto Y, Devoe S, Seto N, Minarchick V, Wilson T, Rothfuss HM, Mohning MP, Arbet J, Kroehl M, Visser A, August J, Thomas SM, Charry LL, Fleischer C, Feser ML, Frazer-Abel AA, Norris JM, Cherrington BD, Janssen WJ, Kaplan MJ, Deane KD, Holers VM, Demoruelle MK. Association of Sputum Neutrophil Extracellular Trap Subsets With IgA Anti-Citrullinated Protein Antibodies in Subjects at Risk for Rheumatoid Arthritis. Arthritis Rheumatol. 2022 01; 74(1):38-48.
Score: 0.006
-
Stenson EK, You Z, Reeder R, Norris J, Scott HF, Dixon BP, Thurman JM, Frazer-Abel A, Mourani P, Kendrick J. Complement Activation Fragments Are Increased in Critically Ill Pediatric Patients with Severe AKI. Kidney360. 2021 12 30; 2(12):1884-1891.
Score: 0.006
-
Sabourin KR, Schultz J, Romero J, Lamb MM, Larremore D, Morrison TE, Frazer-Abel A, Zimmer S, Kedl RM, Jaenisch T, Rochford R. Risk Factors of SARS-CoV-2 Antibodies in Arapahoe County First Responders-The COVID-19 Arapahoe SErosurveillance Study (CASES) Project. J Occup Environ Med. 2021 03 01; 63(3):191-198.
Score: 0.006
-
Mandava N, Tirado-Gonzalez V, Geiger MD, Patnaik JL, Frazer-Abel A, Lynch AM, Mandava N, Palestine AG, Holers VM, Wagner BD, Sanchez-Santos I, Meizner D, Quiroz-Mercado H, Smith JM. Complement Activation in the Vitreous of Patients With Proliferative Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2020 09 01; 61(11):39.
Score: 0.006
-
Kelmenson LB, Wagner BD, McNair BK, Frazer-Abel A, Demoruelle MK, Bergstedt DT, Feser ML, Moss LK, Parish MC, Mewshaw EA, Mikuls TR, Edison JD, Holers VM, Deane KD. Timing of Elevations of Autoantibody Isotypes Prior to Diagnosis of Rheumatoid Arthritis. Arthritis Rheumatol. 2020 02; 72(2):251-261.
Score: 0.006
-
Lynch AM, Mandava N, Patnaik JL, Frazer-Abel AA, Wagner BD, Palestine AG, Mathias MT, Siringo FS, Cathcart JN, Holers VM. Systemic activation of the complement system in patients with advanced age-related macular degeneration. Eur J Ophthalmol. 2020 Sep; 30(5):1061-1068.
Score: 0.005
-
Bemis EA, Norris JM, Seifert J, Frazer-Abel A, Okamoto Y, Feser ML, Demoruelle MK, Deane KD, Banda NK, Holers VM. Complement and its environmental determinants in the progression of human rheumatoid arthritis. Mol Immunol. 2019 08; 112:256-265.
Score: 0.005
-
Rohrer B, Frazer-Abel A, Leonard A, Ratnapriya R, Ward T, Pietraszkiewicz A, O'Quinn E, Adams K, Swaroop A, Wolf BJ. Association of age-related macular degeneration with complement activation products, smoking, and single nucleotide polymorphisms in South Carolinians of European and African descent. Mol Vis. 2019; 25:79-92.
Score: 0.005
-
Thurman JM, Wong M, Renner B, Frazer-Abel A, Giclas PC, Joy MS, Jalal D, Radeva MK, Gassman J, Gipson DS, Kaskel F, Friedman A, Trachtman H. Complement Activation in Patients with Focal Segmental Glomerulosclerosis. PLoS One. 2015; 10(9):e0136558.
Score: 0.004
-
Li HH, Busse P, Lumry WR, Frazer-Abel A, Levy H, Steele T, Dayno J, Riedl M. Comparison of chromogenic and ELISA functional C1 inhibitor tests in diagnosing hereditary angioedema. J Allergy Clin Immunol Pract. 2015 Mar-Apr; 3(2):200-5.
Score: 0.004
-
Shen L, Frazer-Abel A, Reynolds PR, Giclas PC, Chappell A, Pangburn MK, Younis H, Henry SP. Mechanistic understanding for the greater sensitivity of monkeys to antisense oligonucleotide-mediated complement activation compared with humans. J Pharmacol Exp Ther. 2014 Dec; 351(3):709-17.
Score: 0.004
-
Kartalija M, Ovrutsky AR, Bryan CL, Pott GB, Fantuzzi G, Thomas J, Strand MJ, Bai X, Ramamoorthy P, Rothman MS, Nagabhushanam V, McDermott M, Levin AR, Frazer-Abel A, Giclas PC, Korner J, Iseman MD, Shapiro L, Chan ED. Patients with nontuberculous mycobacterial lung disease exhibit unique body and immune phenotypes. Am J Respir Crit Care Med. 2013 Jan 15; 187(2):197-205.
Score: 0.003
-
Lichtenstein KA, Armon C, Nagabhushanam V, Efaw BJ, Frazer-Abel A, Hiserote ME, Alam R. A pilot study to assess inflammatory biomarker changes when raltegravir is added to a virologically suppressive HAART regimen in HIV-1-infected patients with limited immunological responses. Antivir Ther. 2012; 17(7):1301-9.
Score: 0.003
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|